Hims & Hers Health, Inc.
Here’s whether Hims & Hers Health, Inc. (HIMS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+3.31% over 10 days); RSI 45 — healthy momentum range; 3-month momentum positive (+12.4%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -40.3%. Currently 56.9% off its 52-week high. Score: -1/7.
HIMS is trading below its 200-day MA ($29.26) — a key warning sign the longer-term trend is under pressure. An RSI of 44.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -40.3% compares to +20.4% for SPY (trailed the market by 60.6%). The current 56.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.